Evidence map›Paper›PMID 36739328›Full record

Trial reportInternational journal of hematology2023

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.

Chikashi Yoshida, Hiroki Yamaguchi, Noriko Doki, Kazunori Murai, Masaki Iino, Yoshihiro Hatta, Makoto Onizuka, Norio Yokose, Katsumichi Fujimaki, Masao Hagihara and 12 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 1 country.

Chikashi YoshidaDepartment of Hematology, National Hospital Organization Mito Medical Center, 280 Sakuranosato, Ibarakimachi, Higashiibarakigun, Ibaraki, 311-3193, Japan. c.yoshida@mitomedical.org.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Kazunori MuraiDepartment of Hematology, Iwate Prefectural Central Hospital, Morioka, Japan.
Masaki IinoDepartment of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Yoshihiro HattaDivision of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
Makoto OnizukaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Norio YokoseDepartment of Hematology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Katsumichi FujimakiDepartment of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
Masao HagiharaDepartment of Hematology, EIJU General Hospital, Taito-Ku, Japan.
Gaku OshikawaJapanese Red Cross Musashino Hospital, Musashino, Japan.
Kayoko MurayamaDivision of Hematology, Gunma Prefectural Cancer Center, Ohta, Japan.
Takashi KumagaiDepartment of Hematology, Ome Municipal General Hospital, Ome-Shi, Tokyo, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Noriyoshi IriyamaDivision of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
Ikuyo TsutsumiDepartment of Hematology, National Hospital Organization Mito Medical Center, 280 Sakuranosato, Ibarakimachi, Higashiibarakigun, Ibaraki, 311-3193, Japan.
Koji ObaDepartment of Biostatistics, The University of Tokyo, Tokyo, Japan.
Hiroshi KojimaIbaraki Clinical Education and Training Center, University of Tsukuba Hospital, Kasama, Japan.
Hisashi SakamakiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Koiti InokuchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kanto CML Study Group
Tokyo Metropolitan Komagome Hospital · JPNational Hospital Organization Mito Medical Center · JPNihon University · JPNippon Medical School · JPChiba Hokusou Hospital · JPEiju General Hospital · JPFujisawa City Hospital · JPIwate Prefectural Central Hospital · JPMusashino Red Cross Hospital · JPOme Municipal General Hospital · JPSaga University · JPThe University of Tokyo · JPTokai University · JPUniversity of Tsukuba Hospital · JPYamanashi Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment-free remission (TFR) is a new goal for patients with chronic myeloid leukemia in chronic phase (CML-CP) with a sustained deep molecular response (DMR) to treatment with tyrosine kinase inhibitors (TKIs). However, optimal conditions for successful TFR in patients treated with second-generation (2G)-TKIs are not fully defined. In this D-FREE study, treatment discontinuation was attempted in newly diagnosed CML-CP patients treated with the 2G-TKI dasatinib who achieved BCR-ABL1 levels of ≤ 0.0032% (MR4.5) on the international scale (BCR-ABL1

Indexed as

Antineoplastic AgentsDuration of TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTyrosine Kinase InhibitorsAdolescentAdultAgedAged, 80 and overDasatinibFemaleHumansMaleMiddle AgedRemission InductionYoung AdultAntineoplastic AgentsDasatinibTyrosine Kinase InhibitorsChronic myeloid leukemiaDasatinibTreatment-free remission

Identifiers

PMID36739328
PMCPMC10121524
OpenAlexW4319167090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.